TriSalus Life SciencesTLSI
TLSI
About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
0
Funds holding %
of 7,351 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
23% more capital invested
Capital invested by funds: $10M [Q3] → $12.4M (+$2.35M) [Q4]
0.68% more ownership
Funds ownership: 7.41% [Q3] → 8.09% (+0.68%) [Q4]
9% less funds holding
Funds holding: 32 [Q3] → 29 (-3) [Q4]
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
74%
upside
Avg. target
$10.33
80%
upside
High target
$11
91%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Lake Street | 74%upside $10 | Buy Initiated | 13 Feb 2025 |
Roth MKM Jason Wittes 47% 1-year accuracy 9 / 19 met price target | 91%upside $11 | Buy Reiterated | 24 Jan 2025 |
Cantor Fitzgerald Prakhar Agrawal 15% 1-year accuracy 4 / 27 met price target | 74%upside $10 | Overweight Initiated | 17 Dec 2024 |
Financial journalist opinion
Neutral
Business Wire
1 month ago
TriSalus Life Sciences Announces Key Appointments to Board of Directors
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective a.
Neutral
Business Wire
1 month ago
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with OrbiMed, a healthcare investment firm. Pursuant to the to the Agreement, OrbiMed agree.
Neutral
Business Wire
1 month ago
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Full financial results for the year ended December 31, 2024 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $8.3 m.
Neutral
Business Wire
1 month ago
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode.
Positive
Seeking Alpha
2 months ago
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut
TriSalus Life Sciences continues to develop its TriNav infusion system, expanding its reach in liver and pancreatic cancer treatment, despite shifting focus from drug development. TLSI's financials show a $2.4 million net loss for the quarter, but management is optimistic about turning cash flow positive by 2025. The company faces risks with low cash reserves and potential need for dilutive fundraising, despite cost reduction efforts and growing product sales.
Neutral
Seeking Alpha
3 months ago
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & Chief Executive Officer Sean Murphy - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science's Third Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
Neutral
Business Wire
3 months ago
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2024, and provided a business update. “We enter the final quarter of 2024 with great momentum, both commercially and clinically, and we are positioned well for an even greater 2025,” stated Mary Szela,.
Neutral
Business Wire
3 months ago
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC (“Geo-Med”), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System (“TriNav”) to U.S.
Neutral
Business Wire
3 months ago
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients. Highlights of the Launch: Expanded.
Neutral
Business Wire
4 months ago
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter re.
Charts implemented using Lightweight Charts™